These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 33676295)

  • 1. Prognostic and predictive impact of consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer: a translational analysis of the TRIBE2 study.
    Borelli B; Fontana E; Giordano M; Antoniotti C; Lonardi S; Bergamo F; Pietrantonio F; Morano F; Tamburini E; Boccaccino A; Santini D; Zucchelli G; Pella N; Maiello E; Passardi A; Zaniboni A; Ugolini C; Fontanini G; Falcone A; Nyamundanda G; Sadanandam A; Cremolini C
    ESMO Open; 2021 Apr; 6(2):100073. PubMed ID: 33676295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study.
    Moretto R; Giordano M; Poma AM; Passardi A; Boccaccino A; Pietrantonio F; Tomasello G; Aprile G; Lonardi S; Conca V; Granetto C; Frassoldati A; Clavarezza M; Bertolini AS; Germani MM; Ugolini C; Fontanini G; Masi G; Falcone A; Cremolini C
    Eur J Cancer; 2021 Aug; 153():16-26. PubMed ID: 34126333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study.
    Hanna DL; Loupakis F; Yang D; Cremolini C; Schirripa M; Li M; Matsusaka S; Berger MD; Miyamoto Y; Zhang W; Ning Y; Antoniotti C; Salvatore L; Moran M; Zeger G; Astrow SH; Falcone A; Lenz HJ
    Clin Colorectal Cancer; 2018 Sep; 17(3):e471-e488. PubMed ID: 29636300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis.
    Pietrantonio F; Fucà G; Rossini D; Schmoll HJ; Bendell JC; Morano F; Antoniotti C; Corallo S; Borelli B; Raimondi A; Marmorino F; Niger M; Boccaccino A; Masi G; Lonardi S; Boni L; de Braud F; Di Bartolomeo M; Falcone A; Cremolini C
    Oncologist; 2021 Apr; 26(4):302-309. PubMed ID: 33336844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial.
    Mooi JK; Wirapati P; Asher R; Lee CK; Savas P; Price TJ; Townsend A; Hardingham J; Buchanan D; Williams D; Tejpar S; Mariadason JM; Tebbutt NC
    Ann Oncol; 2018 Nov; 29(11):2240-2246. PubMed ID: 30247524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies.
    Antoniotti C; Germani MM; Rossini D; Lonardi S; Pietrantonio F; Santini D; Marmorino F; Allegrini G; Daniel F; Raimondi A; Borelli B; Zaniboni A; Conca V; Abraham J; Spetzler D; Maiello E; Boccaccino A; Passardi A; Giordano M; Tamburini E; Korn MW; Masi G; Cremolini C
    Eur J Cancer; 2022 May; 167():23-31. PubMed ID: 35366570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status.
    Siena S; Rivera F; Taieb J; Peeters M; Prenen H; Koukakis R; Demonty G; Köhne CH
    Clin Colorectal Cancer; 2018 Mar; 17(1):50-57.e8. PubMed ID: 29096990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy-a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest.
    Moretto R; Rossini D; Zucchelli G; Lonardi S; Bergamo F; Santini D; Cupini S; Tomasello G; Caponnetto S; Zaniboni A; Antoniotti C; Pietrantonio F; Buonadonna A; Marmorino F; Bordonaro R; Fea E; Tamburini E; Boccaccino A; Grande R; Aprile G; Falcone A; Cremolini C
    Eur J Cancer; 2020 Nov; 139():81-89. PubMed ID: 32979645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer.
    Loupakis F; Cremolini C; Salvatore L; Masi G; Sensi E; Schirripa M; Michelucci A; Pfanner E; Brunetti I; Lupi C; Antoniotti C; Bergamo F; Lonardi S; Zagonel V; Simi P; Fontanini G; Falcone A
    Eur J Cancer; 2014 Jan; 50(1):57-63. PubMed ID: 24138831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consensus Molecular Subtypes as Biomarkers of Fluorouracil and Folinic Acid Maintenance Therapy With or Without Panitumumab in
    Stahler A; Hoppe B; Na IK; Keilholz L; Müller L; Karthaus M; Fruehauf S; Graeven U; Fischer von Weikersthal L; Goekkurt E; Kasper S; Kind AJ; Kurreck A; Alig AHS; Held S; Reinacher-Schick A; Heinemann V; Horst D; Jarosch A; Stintzing S; Trarbach T; Modest DP
    J Clin Oncol; 2023 Jun; 41(16):2975-2987. PubMed ID: 37018649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies.
    Rossini D; Germani MM; Lonardi S; Pietrantonio F; Dell'Aquila E; Borelli B; Allegrini G; Maddalena G; Randon G; Marmorino F; Zaniboni A; Buonadonna A; Boccaccino A; Conca V; Antoniotti C; Passardi A; Masi G; Cremolini C
    Eur J Cancer; 2022 Jul; 170():64-72. PubMed ID: 35594613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study.
    Personeni N; Rimassa L; Verusio C; Barni S; Rubino L; Bozzarelli S; Villa E; Carnaghi C; Tronconi MC; Gerardi C; Galli F; Floriani I; Destro A; Raschioni C; Labianca R; Santoro A
    Clin Colorectal Cancer; 2015 Sep; 14(3):162-9. PubMed ID: 25861836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
    Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A
    Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO.
    Rossini D; Lonardi S; Antoniotti C; Santini D; Tomasello G; Ermacora P; Germani MM; Bergamo F; Ricci V; Caponnetto S; Moretto R; Zaniboni A; Pietrantonio F; Buonadonna A; Ritorto G; Masi G; Latiano TP; Rapisardi S; Falcone A; Cremolini C
    Br J Cancer; 2021 Jan; 124(1):183-190. PubMed ID: 33024268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).
    Hurwitz HI; Tan BR; Reeves JA; Xiong H; Somer B; Lenz HJ; Hochster HS; Scappaticci F; Palma JF; Price R; Lee JJ; Nicholas A; Sommer N; Bendell J
    Oncologist; 2019 Jul; 24(7):921-932. PubMed ID: 30552157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO.
    Dell'Aquila E; Cremolini C; Zeppola T; Lonardi S; Bergamo F; Masi G; Stellato M; Marmorino F; Schirripa M; Urbano F; Ronzoni M; Tomasello G; Zaniboni A; Racca P; Buonadonna A; Allegrini G; Fea E; Di Donato S; Chiara S; Tonini G; Tomcikova D; Boni L; Falcone A; Santini D
    Ann Oncol; 2018 Apr; 29(4):924-930. PubMed ID: 29324972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
    García-Alfonso P; Benavides M; Falcó E; Muñoz A; Gómez A; Sastre J; Rivera F; Montagut C; Salgado M; López-Ladrón A; López R; Ruiz de Mena I; Durán G; Aranda E;
    Oncologist; 2018 Nov; 23(11):1271-e128. PubMed ID: 30120161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial.
    Schirripa M; Zhang W; Heinemann V; Cao S; Okazaki S; Yang D; Loupakis F; Berger MD; Ning Y; Miyamoto Y; Suenaga M; Gopez RF; West JD; Hanna D; Barzi A; Falcone A; Stintzing S; Lenz HJ
    Int J Cancer; 2017 Jul; 141(2):383-392. PubMed ID: 28369940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic and Predictive Role of Body Mass Index (BMI) in Metastatic Colorectal Cancer (mCRC): A Pooled Analisys of Tribe and Tribe-2 Studies by GONO.
    Dell'Aquila E; Rossini D; Galletti A; Stellato M; Boccaccino A; Conca V; Germani MM; Bergamo F; Daniel F; Spagnoletti A; Provenzano L; Tomasello G; Zaniboni A; Buonadonna A; Fanchini L; Cupini S; Carlomagno C; Caponnetto S; Rapisardi S; Santini D
    Clin Colorectal Cancer; 2022 Sep; 21(3):220-228. PubMed ID: 35304089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials.
    Cremolini C; Loupakis F; Masi G; Lonardi S; Granetto C; Mancini ML; Chiara S; Moretto R; Rossini D; Vitello S; Allegrini G; Tonini G; Bergamo F; Tomasello G; Ronzoni M; Buonadonna A; Bustreo S; Barbara C; Boni L; Falcone A
    Ann Oncol; 2016 May; 27(5):843-9. PubMed ID: 26861604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.